Ultrasound and clinicopathological characteristics of triple receptor-negative breast cancers

Journal of Breast Cancer

Volumn 14, Issue 2, 2011, Pages 119-123

  Choi, Yoon Jung ^a   Seong, Min Hyun ^b   Choi, Seon Hyeong ^a   Kook, Shin Ho ^a   Kwag, Hyon Joo ^a   Park, Yong Lai ^a   Park, Chan Heun ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Dream Hospital   (South Korea)

Author keywords

Breast neoplasms; Hormone receptor; Pathology; Ultrasouography

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CALCIFICATION; BREAST CARCINOMA; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; ECHOGRAPHY; HISTOPATHOLOGY; HOSPITAL PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; PHENOTYPE; TRIPLE NEGATIVE BREAST CANCER; TUMOR DIFFERENTIATION; TUMOR VOLUME;

EID: 79959837765     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2011.14.2.119     Document Type: Article

References (23)

1. Akiyama F, Iwase H. Triple negative breast cancer: clinicopathological characteristics and treatment strategies. Breast Cancer 2009;16:252-253.
2. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007;109:1721-1728.
3. Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: review. Pathology 2009;41:40-47.
4. Sasaki Y, Tsuda H. Clinicopathological characteristics of triple-negative breast cancers. Breast Cancer 2009;16:254-259.
5. Elias AD. Triple-negative breast cancer: a short review. Am J Clin Oncol 2010;33:637-645.
6. Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 2009;45:2792-2798.
7. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-2334.
8. Tian XS, Cong MH, Zhou WH, Zhu J, Chen YZ, Liu Q. Clinicopathologic and prognostic characteristics of triple-negative breast cancer. Onkologie 2008;31:610-614.
9. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109: 25-32.
10. Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 2005;103:2241-2251.
11. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-2502.
12. Tan GH, Taib NA, Choo WY, Teo SH, Yip CH. Clinical characteristics of triple-negative breast cancer: experience in an Asian developing country. Asian Pac J Cancer Prev 2009;10:395-398.
13. Ahn SH, Hwang UK, Kwak BS, Yoon HS, Ku BK, Kang HJ, et al. Prevalence of BRCA1 and BRCA2 mutations in Korean breast cancer patients. J Korean Med Sci 2004;19:269-274.
14. Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea: a report from the Korean Breast Cancer Society. J Clin Oncol 2007;25:2360-2368.
15. Yoo KY, Kang D, Park SK, Kim SU, Kim SU, Shin A, et al. Epidemiology of breast cancer in Korea: occurrence, high-risk groups, and prevention. J Korean Med Sci 2002;17:1-6.
16. Seo BK, Pisano ED, Kuzimak CM, Koomen M, Pavic D, Lee Y, et al. Correlation of HER-2/neu overexpression with mammography and age distribution in primary breast carcinomas. Acad Radiol 2006;13:1211-1218.
17. Yang WT, Dryden M, Broglio K, Gilcrease M, Dawood S, Dempsey PJ, et al. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat 2008; 111:405-410.
18. Wang Y, Ikeda DM, Narasimhan B, Longacre TA, Bleicher RJ, Pal S, et al. Estrogen receptor-negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression. Radiology 2008;246:367-375.
19. Ko ES, Lee BH, Kim HA, Noh WC, Kim MS, Lee SA. Triple-negative breast cancer: correlation between imaging and pathological findings. Eur Radiol 2010;20:1111-1117.
20. Karamouzis MV, Likaki-Karatza E, Ravazoula P, Badra FA, Koukouras D, Tzorakoleftherakis E, et al. Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors. Int J Cancer 2002;102:86-90.
21. Field AS, Chamberlain NL, Tran D, Morey AL. Suggestions for HER-2/neu testing in breast carcinoma, based on a comparison of immunohistochemistry and fluorescence in situ hybridisation. Pathology 2001;33: 278-282.
22. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004;291:1972-1977.
23. Yaziji H, Gown AM. Testing for epidermal growth factor receptor in lung cancer: have we learned anything from HER-2 testing? J Clin Oncol 2004;22:3646.